$18.30
+0.46 (+2.58%)
Open$18.21
Previous Close$17.84
Day High$18.41
Day Low$18.11
52W High$25.15
52W Low$10.96
Volume—
Avg Volume601.9K
Market Cap966.93M
P/E Ratio15.91
EPS$0.81
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+172.2% upside
Current
$18.30
$18.30
Target
$49.81
$49.81
$29.15
$49.81 avg
$64.16
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 302.88M | 291.12M | 329.37M |
| Net Income | 47.68M | 41.25M | -60,795,749 |
| Profit Margin | 15.7% | 15.0% | -18.5% |
| EBITDA | 39.58M | 36.14M | -79,903,104 |
| Free Cash Flow | — | — | -60,969,564 |
| Rev Growth | +4.0% | +4.0% | -9.3% |
| Debt/Equity | — | — | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |